tbuckley/cabot-search huggingface dataset:
Letter to the editor: Leveraging universal adult vaccination as part of a multipronged approach to eliminate hepatitis B in the USA
Authors: Vivian Huang, Clem Lewin, Patricia Novy
Journal: Hepatology (2022)

To the editor, We agree with Cohen et al.[1] that universal hepatitis B screening followed by linkage to care offers a cost‐effective and destigmatizing solution to diagnose and treat people living with chronic infection. Elimination of hepatitis B in the USA by 2030 requires a comprehensive approach, in which successful implementation of an immunization program to prevent infection of susceptible adults will be critical. In November 2021, recognizing the shortcomings of existing risk‐based recommendations, the Advisory Committee on Immunization Practices (ACIP) expanded and simplified recommendations for hepatitis B vaccination to include all adults ages 19–59 years and ≥ 60 years with risk factors for hepatitis B infection. Adults ≥ 60 years of age without known risk factors for hepatitis B infection may receive hepatitis B vaccines.[2] Cohen et al. suggest that universal screening with the three‐test panel (HBsAg, HBsAb, and HBcAb) will identify susceptible persons benefiting from vaccination. In this context, ACIP recommends that serologic testing, if performed, should not be a barrier to vaccination of susceptible persons.[3] The first dose of vaccine should typically be administered immediately after collection of the blood sample. Therefore, screening and immunization would optimally be performed at the same visit, as opposed to waiting for the results of screening to immunize a susceptible individual. Prevention through universal vaccination is an essential component of a multipronged approach to disease elimination. Given the disparities in access to health care, health equity can be improved by minimizing the number of visits needed to achieve series completion. If universal screening is implemented, screening and initiating immunization at the same visit will be paramount in our collaborative efforts to eliminate hepatitis B in the USA by 2030. CONFLICT OF INTEREST Dr. Lewin consults for Dynavax Technologies. Dr. Novy owns stock in and is employed by Dynavax. She owns stock in Glaxo Smith Kline and Moderna. Dr. Huang owns stock in and is employed by Dynavax.
Use of epinephrine in paedriatric anaphylaxis: beyond the emergency department
Authors: Maria Munoz de Baena Albarracin, Filip Skrabski, Esperanza Pérez-Pallisé, Irene Vázquez -Barrera, María Luisa Baeza, ALberto Alvarez-Perea
Journal: Journal of Allergy and Clinical Immunology (2022)
Adolescent medicine
Authors: C. E. Irwin
Journal: JAMA (1992)

As we proceed through the 1990s, developments at the national level that began in the 1980s are now coming to fruition. Private foundations, the federal government, professional medical organizations, and medical certifying boards have played major roles in bringing the issues regarding adolescence to the national agenda. In the arena of private foundations, the Robert Wood Johnson Foundation, Princeton, NJ, supported the development of community programs to provide health services to high-risk youth in community-based clinics linked to university medical centers and through school-based clinics. School-based clinics have now emerged as one community model that increases access to primary health care services for adolescents. The William T. Grant Foundation Commission on Work, Family and Citizenship, New York, NY, brought our attention to the problems of young adults and the social and economic plight of young families.<sup>1</sup>The Carnegie Council on Adolescent Development, established in 1987 by the Carnegie Corporation
Move Over, Harrods
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Facile one-step synthesis of NIR-Responsive siRNA-Inorganic hybrid nanoplatform for imaging-guided photothermal and gene synergistic therapy
Authors: Xiuna Jia, Mengmeng Lv, Yunwei Fei, Qing Dong, Hao Wang, Qiong Liu, Dan Li, Jin Wang, Erkang Wang
Journal: Biomaterials (2022)
Long-acting injectable ART for HIV: a (cautious) step forward
Authors: Priya Venkatesan
Journal: The Lancet Microbe (2022)

HIV is still a major incurable global health problem, with an estimated 37·7 million people (95% CI 30·2–45·1) living with the virus at the end of 2020. However, access to antiretroviral therapy (ART) has enabled the effective treatment and prevention of HIV infection and related disease, substantially reducing the associated mortality and morbidity.
References and Reviews
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Three-dimensional (3D) scaffolds as powerful weapons for tumor immunotherapy
Authors: Shuyan Han, Jun Wu
Journal: Bioactive Materials (2022)

Though increasing understanding and remarkable clinical successes have been made, enormous challenges remain to be solved in the field of cancer immunotherapy. In this context, biomaterial-based immunomodulatory strategies are being developed to boost antitumor immunity. For the local immunotherapy, macroscale biomaterial scaffolds with 3D network structures show great superiority in the following aspects: facilitating the encapsulation, localized delivery, and controlled release of immunotherapeutic agents and even immunocytes for more efficient immunomodulation. The concentrating immunomodulation
Point-of-care treatment of geometrically complex midfacial critical-sized bone defects with 3D-Printed scaffolds and autologous stromal vascular fraction
Authors: Srujan Singh, Ethan L. Nyberg, Aine N. O'Sullivan, Ashley Farris, Alexandra N. Rindone, Nicholas Zhang, Emma C. Whitehead, Yuxiao Zhou, Eszter Mihaly, Chukwuebuka C. Achebe, Wojciech Zbijewski, Will Grundy, David Garlick, Nicolette D. Jackson, Takashi Taguchi, Catherine Takawira, Joseph Lopez, Mandi J. Lopez, Michael P. Grant, Warren L. Grayson
Journal: Biomaterials (2022)

Critical-sized midfacial bone defects present a unique clinical challenge due to their complex three-dimensional shapes and intimate associations with sensory organs. To address this challenge, a point-of-care treatment strategy for functional, long-term regeneration of 2 cm full-thickness segmental defects in the zygomatic arches of Yucatan minipigs is evaluated. A digital workflow is used to 3D-print anatomically precise, porous, biodegradable scaffolds from clinical-grade poly-ε-caprolactone and decellularized bone composites. The autologous stromal vascular fraction of cells (SVF) is isolated from adipose tissue extracts and infused into the scaffolds that are implanted into the zygomatic ostectomies. Bone regeneration is assessed up to 52 weeks post-operatively in acellular (AC) and SVF groups (BV/DV = 0.64 ± 0.10 and 0.65 ± 0.10 respectively). In both treated groups, bone grows from the adjacent tissues and restores the native anatomy. Significantly higher torque is required to fracture the bone-scaffold interface in the SVF (7.11 ± 2.31 N m) compared to AC groups (2.83 ± 0.23 N m). Three-dimensional microcomputed tomography analysis reveals two distinct regenerative patterns: osteoconduction along the periphery of scaffolds to form dense lamellar bone and small islands of woven bone deposits growing along the struts in the scaffold interior. Overall, this study validates the efficacy of using 3D-printed bioactive scaffolds with autologous SVF to restore geometrically complex midfacial bone defects of clinically relevant sizes while also highlighting remaining challenges to be addressed prior to clinical translation.
THE PATENT MEDICINE CONSPIRACY AGAINST THE FREEDOM OF THE PRESS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Journal of Clinical Investigation, Boston
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P11.01 Phase I Trial of in Situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC
Authors: A. Lisberg, B. Liu, R. Salehi-Rad, J. Lee, L. Tran, K. Kostyantyn, R. Lim, C. Dumitras, Z. Jing, F. Abtin, R. Suh, S. Genshaft, G. Fishbein, A. Kaul, K. Kahlon, S. Ashouri, J. Goldman, D. Elashoff, E. Garon, S. Dubinett
Journal: Journal of Thoracic Oncology (2021)
Mrs. K
Authors: Sharon Hull
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>A Text-Book of Psychiatry for Students and Practitioners.</i>By D. K. Henderson, M. D. (Edin.), F. R. C. P. S. (Glas.) Physician-Superintendent The Glasgow Royal Mental Hospital; Lecturer in Psychological Medicine, University of Glasgow, etc., and R. D. Gillespie, M. D. (Glas.), D. P. M. (Lond.), Physician for Psychological Medicine, Guy's Hospital, London; Lecturer in Psychological Medicine, Guy's Hospital Medical School, etc. (<i>London: Humphrey Milford, Oxford University Press, 1927.</i>)
Authors: E. N. B.
Journal: American Journal of Psychiatry (1929)
Mental Hygiene in the Community
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of a nasal decongestant. Oxymetazoline hydrochloride (Afrin)
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer
Authors: Adele M. Nicolas, Marina Pesic, Esther Engel, Paul K. Ziegler, Markus Diefenhardt, Kilian B. Kennel, Florian Buettner, Claire Conche, Valentina Petrocelli, Eiman Elwakeel, Andreas Weigert, Anna Zinoveva, Maximilian Fleischmann, Björn Häupl, Cem Karakütük, Hanibal Bohnenberger, Mohammed H. Mosa, Lars Kaderali, Jochen Gaedcke, Michael Ghadimi, Franz Rödel, Melek C. Arkan, Thomas Oellerich, Claus Rödel, Emmanouil Fokas, Florian R. Greten
Journal: Cancer Cell (2022)

Standard cancer therapy targets tumor cells without considering possible damage on the tumor microenvironment that could impair therapy response. In rectal cancer patients we find that inflammatory cancer-associated fibroblasts (iCAFs) are associated with poor chemoradiotherapy response. Employing a murine rectal cancer model or patient-derived tumor organoids and primary stroma cells, we show that, upon irradiation, interleukin-1α (IL-1α) not only polarizes cancer-associated fibroblasts toward the inflammatory phenotype but also triggers oxidative DNA damage, thereby predisposing iCAFs to p53-mediated therapy-induced senescence, which in turn results in chemoradiotherapy resistance and disease progression. Consistently, IL-1 inhibition, prevention of iCAFs senescence, or senolytic therapy sensitizes mice to irradiation, while lower IL-1 receptor antagonist serum levels in rectal patients correlate with poor prognosis. Collectively, we unravel a critical role for iCAFs in rectal cancer therapy resistance and identify IL-1 signaling as an attractive target for stroma-repolarization and prevention of cancer-associated fibroblasts senescence.
The immeasurable value of peer reviewers
Authors: Onisillos Sekkides
Journal: The Lancet Microbe (2022)

Peer review is the crucial underpinning of any journal. So, the early success of The Lancet Microbe has depended on those who are generous enough to contribute their time and expertise despite our initial lack of status. These people have invested themselves in our journal's success because they value the scientific endeavour in general and maintaining the quality of their own fields in particular. This generosity, while we are still establishing ourselves, is why I want to take the time to express my personal gratitude. You are as much a part of this journal as me, my colleagues, and the authors. There is insufficient recognition of the importance of peer review. To address this in a small way we have published a list of people who have peer reviewed manuscripts for us. I also want to thank the many people who we have invited to review manuscripts, but who were unable. These have been an exceptionally busy couple of years for everybody and taking the time to let us know that you might be interested in reviewing in the future is still helpful. Those among you who were unable to review but recommended colleagues who might be interested were an even greater help. Thanks again to all who have contributed to the peer review of manuscripts submitted to us. I look forward to the benefit of your advice in the future. Thank you to The Lancet Microbe clinical and statistical peer reviewers in 2021Laith Abu-Raddad Full-Text PDF Open Access
All roads lead to universal health coverage
Authors: Tedros Adhanom Ghebreyesus
Journal: The Lancet Global Health (2017)

All roads lead to universal health coverage—and this is our top priority at WHO. For me, the key question of universal health coverage is an ethical one. Do we want our fellow citizens to die because they are poor? Or millions of families impoverished by catastrophic health expenditures because they lack financial risk protection? Universal health coverage is a human right.
Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma
Authors: Ningna Weng, Siyuan Qin, Jiayang Liu, Xing Huang, Jingwen Jiang, Li Zhou, Zhe Zhang, Na Xie, Kui Wang, Ping Jin, Maochao Luo, Liyuan Peng, Edouard C. Nice, Ajay Goel, Suxia Han, Canhua Huang, Qing Zhu
Journal: Acta Pharmaceutica Sinica B (2022)

Pancreatic ductal adenocarcinoma (PDAC) is characterized by the highest mortality among carcinomas. The pathogenesis of PDAC requires elevated autophagy, inhibition of which using hydroxychloroquine has shown promise. However, current realization is impeded by its suboptimal use and unpredictable toxicity. Attempts to identify novel autophagy-modulating agents from already approved drugs offer a rapid and accessible approach. Here, using a patient-derived organoid model, we performed a comparative analysis of therapeutic responses among various antimalarial/fungal/parasitic/viral agents, through which econazole (ECON), an antifungal compound, emerged as the top candidate. Further testing in cell-line and xenograft models of PDAC validated this activity, which occurred as a direct consequence of dysfunctional autophagy. More specifically, ECON boosted autophagy initiation but blocked lysosome biogenesis. RNA sequencing analysis revealed that this autophagic induction was largely attributed to the altered expression of activation transcription factor 3 (ATF3). Increased nuclear import of ATF3 and its transcriptional repression of inhibitor of differentiation-1 (ID-1) led to inactivation of the AKT/mammalian target of rapamycin (mTOR) pathway, thus giving rise to autophagosome accumulation in PDAC cells. The magnitude of the increase in autophagosomes was sufficient to elicit ER stress-mediated apoptosis. Furthermore, ECON, as an autophagy inhibitor, exhibited synergistic effects with trametinib on PDAC. This study provides direct preclinical and experimental evidence for the therapeutic efficacy of ECON in PDAC treatment and reveals a mechanism whereby ECON inhibits PDAC growth.